| Michael B Hopkins, PHD | |
|
26 Midway St, Bristol, TN 37620-1706 | |
| (423) 989-4500 | |
| (423) 467-3644 |
| Full Name | Michael B Hopkins |
|---|---|
| Gender | Male |
| Speciality | Psychologist |
| Location | 26 Midway St, Bristol, Tennessee |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821303587 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | (* (Not Available)) | Secondary |
| 103T00000X | Psychologist | 3043 (Tennessee) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael B Hopkins, PHD 1167 Spratlin Park Dr, Gray, TN 37615-6205 Ph: (423) 467-3600 | Michael B Hopkins, PHD 26 Midway St, Bristol, TN 37620-1706 Ph: (423) 989-4500 |
News Archive
The best way to prevent the spread of disease in rural areas may be by targeting select popular hangouts, according to a new study by the Kansas State University EpiCenter research team.The team published "Efficient Mitigation Strategies for Epidemics in Rural Regions" in the July edition of the journal PLoS ONE. The study looks at mitigation strategies based on a contact network model developed using information collected from residents in Clay County, Kan.
This week researchers in the Oregon Health & Science University (OHSU) Oregon Stem Cell Center and the OHSU Digestive Health Center are shining a new ray of hope on patients with pancreatic cancer. They've developed new reagents, or antibodies, that can recognize this often lethal disease. This important discovery may one day lead to earlier detection and treatment.
BRCA1 and BRCA2 are two genes that have been identified to hold a key to women's susceptibility to get breast or ovarian cancer. Changes also known as mutations in these genes are significant in women who go on to develop breast or ovarian cancer. Melbourne-based company Genetic Technologies Limited (GTL) has the exclusive license from American biotechnology company Myriad Genetics to carry out testing for the genes in Australia. Myriad holds a patent for these genes.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established branded drugs such as, Centocor Ortho Biotech's Remicade, Abbott's Humira and Amgen/Wyeth's Enbrel, in this class will face competition from newer entrants.
Australian adult stem cell company, Mesoblast Limited, today announced that its chief scientific advisor and founder, Professor Silviu Itescu, has been awarded a $1.5 million grant for pre-clinical and clinical development of mesenchymal lineage adult stem cells.
› Verified 7 days ago